https://www.taxtmi.com/news?id=73492 India's pharmaceutical supply chain remains heavily dependent on Chinese imports for critical active pharmaceutical ingredients, key starting materials and intermediates. Rising environmental compliance requirements have increased manufacturing and research and development costs, while weak innovation and a limited commercialisation ecosystem create uncertainty for innovators and long-term investment. The report calls for diversification into higher-value pharmaceutical segments, greater regulatory transparency, and stronger industry-academia technology transfer to support patent commercialisation, research collaboration and startup incubation. en-us Tue, 23 Jun 2026 16:01:04 +0530 Tue, 23 Jun 2026 16:01:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=73492 India's pharmaceutical supply chain remains heavily dependent on Chinese imports for critical active pharmaceutical ingredients, key starting materials and intermediates. Rising environmental compliance requirements have increased manufacturing and research and development costs, while weak innovation and a limited commercialisation ecosystem create uncertainty for innovators and long-term investment. The report calls for diversification into higher-value pharmaceutical segments, greater regulatory transparency, and stronger industry-academia technology transfer to support patent commercialisation, research collaboration and startup incubation. News - Tue, 23 Jun 2026 16:01:04 +0530 https://www.taxtmi.com/news?id=73492